Colorectal - oncology - SA Health Approved Cancer Chemotherapy Protocol Register

Adjuvant and neoadjuvant

Adjuvant and Neoadjuvant
Protocol Administration at chemotherapy unit level Review Date
Colorectal adjuvant capecitabine Low February 2023
Colorectal adjuvant CAPOX (XELOX) (Capecitabine and Oxaliplatin)
The SA Health Cancer Drug Committee has approved this protocol for the additional indication: Neoadjuvant therapy prior to definitive surgery
Medium February 2023
Colorectal adjuvant de Gramont (modified) (fluorouracil and leucovorin) Low February 2023
Colorectal adjuvant FOLFOX6 (Modified) (fluorouracil leucovorin oxaliplatin)
The SA Health Cancer Drug Committee has approved this protocol for the additional indication: Neoadjuvant therapy prior to definitive surgery
Medium2 February 2023
Colorectal adjuvant QUASAR (Modified) fluorouracil leucovorin weekly Low February 2023

Metastatic

Metastatic
Protocol Administration at chemotherapy unit level Review Date
Colorectal metastatic capecitabine Low February 2023
Colorectal metastatic capecitabine and bevacizumab Low February 2023
Colorectal metastatic CAPIRI (XELIRI) (capecitabine irinotecan) Medium February 2022
Colorectal metastatic CAPIRI (XELIRI) (capecitabine irinotecan) and bevacizumab Medium February 2022
Colorectal metastatic CAPOX (XELOX) (capecitabine and oxaliplatin) Medium February 2023
Colorectal metastatic CAPOX (XELOX) (capecitabine and oxaliplatin) and bevacizumab Medium February 2023
Colorectal metastatic cetuximab (two weekly) Low February 2025
Colorectal metastatic de Gramont (modified) (fluorouracil and leucovorin) Low2 February 2023
Colorectal metastatic FOLFIRI (modified) (fluorouracil leucovorin irinotecan) Medium2 February 2023
Colorectal metastatic FOLFIRI (modified) (fluorouracil leucovorin irinotecan) and bevacizumab Medium2 February 2023
Colorectal metastatic FOLFIRI (modified) (fluorouracil leucovorin irinotecan) and cetuximab Medium2
February 2023
Colorectal metastatic FOLFIRI (modified) (fluorouracil leucovorin irinotecan) and panitumumab.
The SA Health Cancer  Drug Committee have approved this protocol for the amended indication: Treatment of patients with RAS wild-metastatic colorectal cancer
Medium2 February 2023
Colorectal metastatic FOLFIRI (modified) (fluorouracil leucovorin irinotecan) and cetuximab (two weekly) Medium2 February 2023
Colorectal metastatic FOLFOX6 (modified) (fluorouracil leucovorin oxaliplatin) Medium2 February 2025
Colorectal metastatic FOLFOX6 (modified) (fluorouracil leucovorin oxaliplatin) and bevacizumab Medium2 February 2023
Colorectal metastatic FOLFOX6 (modified) (fluorouracil leucovorin oxaliplatin) and cetuximab Medium2 February 2023
Colorectal metastatic FOLFOX6 (modified) (fluorouracil leucovorin oxaliplatin) and panitumumab Medium2 February 2023
Colorectal metastatic FOLFOXIRI (modified) (fluorouracil leucovorin oxaliplatin irinotecan)
Medium February 2023
Colorectal metastatic FOLFOXIRI (modified) (fluorouracil leucovorin oxaliplatin irinotecan) with bevacizumab
Medium February 2023
Colorectal metastatic irinotecan three weekly Medium August 2021
Colorectal metastatic irinotecan 2-weekly. For information on this protocol please contact the SA Health Cancer Drug Committee) Medium December 2021
Colorectal metastatic irinotecan and panitumumab. For information on this protocol please contact the SA Health Cancer Drug Committee) Medium December 2021
Colorectal metastatic panitumumab Low February 2023
Colorectal metastatic QUASAR (modified) fluorouracil and leucovorin weekly Low February 2023
Colorectal metastatic raltitrexed Medium February 2023
Colorectal metastatic raltitrexed and oxaliplatin3.
For information on this protocol please contact the SA Health Cancer Drug Committee
).
Medium March 2022
Colorectal metastatic regorafenib3 Low August 2021
Colorectal metastatic Roswell Park (modified) fluorouracil and leucovorin weekly Low February 2023
Colorectal metastatic Roswell Park (modified) fluorouracil leucovorin weekly and bevacizumab Low February 2023
Metastatic trifluridine/tipiracil
Low August 2021

Anal

Anal
Protocol Administration at chemotherapy unit level Review Date
Anal advanced cARBOplatin and PACLitaxel Medium February 2022
Anal definitive cISplatin and fluorouracil chemoradiation Medium2 August 2021
Anal definitive mitomycin and capecitabine chemoradiation Medium February 2021
Anal definitive mitomycin and fluorouracil chemoradiation Medium2 February 2023

Rectal

Rectal
Protocol Administration at chemotherapy unit level Review Date
Rectal locally advanced capecitabine chemoradiation Medium August 2021
Rectal locally advanced fluorouracil (protracted Infusion) chemoradiation Medium2 February 2023
Rectal Neoadjuvant/adjuvant CAPOX – Interim “Radiotherapy may be scheduled before or after systemic cancer therapy as appropriate to individual patient treatment plan” (for information on this protocol please contact the SA Health Cancer Drug Committee)
Medium November 2021
Rectal Neoadjuvant/adjuvant FOLFOX – Interim “Radiotherapy may be scheduled before or after systemic cancer therapy as appropriate to individual patient treatment plan” (for information on this protocol please contact the SA Health Cancer Drug Committee) Medium2 November 2021

Notes

  1. Permitted to be administered in low-risk units for second and subsequent cycles for patients with ECOG performance status 0 or 1 showing ≤ Grade 1 toxicity
  2. Fluorouracil pumps may be connected/disconnected at low-risk units
  3. Non-formulary drug included in the protocol
  4. Continuation dual treatment with pertuzumab and trastuzumab can be provided to appropriate patients at low-risk chemotherapy units.